Effect of Indoor Air Quality Improvement on Health in Patients With Interstitial Lung Disease

Air pollution threatens the respiratory health of patients with interstitial lung disease (ILD). High-efficiency air purifiers, featuring easy operation and excellent particulate matter removal efficiency, have been shown in previous studies to potentially delay lung function deterioration and reduce acute exacerbation risk in respiratory disease patients. This randomized crossover study employs air purifiers to filter indoor gaseous pollutants, allergens, and other contaminants, aiming to alleviate respiratory irritation, improve daily life comfort, and enhance overall health status in ILD patients.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

ILD

Age range

19 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients diagnosed with interstitial lung disease (ILD).
Stable disease status, defined as no hospitalization due to acute exacerbation within the past month.

Exclusion criteria

Patients with complications of severe organ failure (including heart, liver, or kidney failure), malignant tumors, or mental disorders.
A history of respiratory tract infection within the past two weeks.

Treatment and study plan

Air Purifier (with Filter) Arm

Behavioral

Place an air purifier with high-efficiency filters in the home, and turn it on for at least 18 hours every day.

Purifier (without Filter) Arm

Behavioral

Place an air purifier without a filter in the home.

Primary outcomes

Symptom Improvement-related Indicators (e.g., Improvement in Respiratory Symptom Score)

Time frame: Baseline (before intervention), Week 2 (end of first phase), Week 6 (end of second phase)

St. George's Respiratory Questionnaire (SGRQ):Score Range:Minimum score: 0 points;Maximum score: 100 points.A higher score indicates worse outcomes for the patient.
Pulmonary Function Indicators (e.g., Pulmonary Diffusing Capacity)

Time frame: Baseline (before intervention), Week 2 (end of first phase), Week 6 (end of second phase)
Quality of Life Indicators (e.g., CAT Score)

Time frame: Baseline (before intervention), Week 2 (end of first phase), Week 6 (end of second phase)

COPD Assessment Test (CAT):It is a short, validated, patient-reported outcome (PRO) tool specifically designed to measure the impact of pulmonary disease on a patient's health status and daily life.Score Range:Minimum score: 0 points;Maximum score: 40 points.A higher score indicates worse health status and greater pulmonary disease-related burden for the patient.
Blood Sample Indicators (e.g., Concentration of Interleukin-8)

Time frame: Baseline (before intervention), Week 2 (end of first phase), Week 6 (end of second phase)

Assessment of Changes in Pulmonary Inflammation or Lung Injury Before and After Intervention Using Concentrations of Biomarkers Such as Interleukin-8

Sponsors and collaborators

Lead sponsor

Peking Union Medical College

Other

Registry information

Official study title

A Randomized Crossover Trial of Indoor Air Quality Improvement on Health in Patients With Interstitial Lung Disease

Important dates

Study start: 2026
Primary completion: 2026
Study completion: 2027
First posted: Jan 15, 2026
Registry last updated: Jan 15, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not Yet Recruiting